Introduction
Focal adhesion kinase (FAK) is a non-receptor-type tyrosine kinase that plays a crucial role in integrin-mediated cellular interaction between the intracellular cytoskeleton and the extracellular matrix, as well as in growth factor-and cytokine receptor-mediated pathways [1] . As a part of focal adhesions, FAK is essential for tumorigenesis by regulating adhesion-independent cell growth, proliferation, survival, migration, invasion and angiogenesis [2] . Several studies have shown an association between high expression of FAK and/or fak gene amplification and progression to an invasive cell phenotype, including breast cancer (BC) [3, 4] , whereas in benign breast tissue FAK expression is rarely detectable [5] . Cance and colleagues [5, 6] showed that FAK was upregulated in BC. Because of moderate levels for FAK expression in pre-invasive ductal carcinoma in situ cells, the authors concluded that high expression of FAK may be an early event in carcinogenesis of BC. Regarding the prognostic role of FAK in BC, studies have conflicting results. Other studies describe FAK associated with suppression of mammary tumorigenesis, and that silencing FAK reduces the pool of cancer stem cells in mice [2] and reduces mammary tumor formation [7] .
The aim of the current study was to examine the prognostic impact of FAK in an untreated cohort of lymph node-negative BC patients with a focus on different molecular subtypes.
Patients and Methods

Patient Cohorts
To determine the prognostic impact of FAK we selected patients with nodenegative BC treated between 1985 and 2000 at the University Hospital Mainz, who did not receive any adjuvant treatment modalities after tumor resection. Patients with available tumor samples and consistent information on follow-up entered this retrospective explorative study. The initial study cohort consisted of 410 consecutive lymph node-negative BC patients. Tumor tissue for FAK im-
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Results
Patient Cohorts
We screened 410 consecutive patients with lymph node-negative BC. For 335 patients FFPE tissue was available and these entered the study for FAK immunohistochemistry. The mean followup time for the entire cohort was 183 months (range 0-348 months 
Immunohistochemistry
Representative pictures of FAK immunostaining are shown in figure 1 and present a mainly cytoplasmic and occasionally membranous staining. As described before, tissue samples were divided into FAK high/positive (multiplication product of 6, 45.1%, n = 151) and low/negative (all other cases, 54.9%, n = 184) expressing samples (table 1) .
Correlation of FAK and Clinico-Pathological Variables
When we performed correlation analyses using chi-square tests with FAK and the categorized clinico-pathological variables age, tumor size, histological grade of differentiation, ER, PR and HER2, only ER showed a significant correlation with FAK (p = 0.043).
Association of FAK with DFS
High expression of FAK was associated with better DFS (hazard ratio (HR) 1.54, 95% confidence interval (CI) 1.04-2.28, p = 0.030) (table 2). Kaplan-Meier plots revealed a 76.9% 5-year DFS rate for FAK-positive and an 84.5% 5-year DFS rate for FAK-negative patients (p = 0.028) ( fig. 2 ). In addition to FAK tumor size (HR 1.67, 95% CI 1.13-2.47, p = 0.010), grading (HR 3.10, 95% CI 2.08-4.63, p = <0.001), ER status (HR 0.58, 95% CI 0.38-0.88, p = 0.011), HER2 status (HR 2.48, 95% CI 1.54-3.98, p = <0.002) and Ki-67 (HR 1.85, 95% CI 1.23-2.77, p = 0.003) showed significant influence in univariate analysis (table 2) . However, in multivariate analmunohistochemistry was available for 335 patients. Adequate follow-up information of all patients was available. Patients were treated either with modified radical mastectomy (44%) or breast-conserving surgery followed by irradiation (56%). All patients received a complete axillary dissection. They did not receive any systemic therapy in the adjuvant setting. Patient and tumor characteristics were collected retrospectively in a previously published BC database [8] . The study was approved by the ethical review board of the medical association of Rhineland-Palatinate. The study was conducted according to the reporting recommendations for tumor marker reporting studies [9] .
Immunohistochemistry
Immunohistochemical staining for FAK was performed according to standard procedures. Briefly, 4-μm-thick serial section of formalin-fixed and paraffin-embedded (FFPE) tumor tissue slides were incubated with the primary antibody in a dilution of 1: 100 (rabbit anti-human-FAK antibody, Cell Signaling Technology), followed by polymeric biotin-free visualization system (Envision TM ; DAKO Diagnostic Company, Hamburg, Germany). Finally, the sections were counterstained with Mayer's hematoxylin solution (Sigma-Aldrich ® ). We used a BC sample strongly positive for FAK as a positive control. Negative controls were prepared by substituting normal mouse serum for primary antibody, and no detectable staining was evident. is not yet standardized, we used the scoring system for estrogen receptor (ER) and progesterone receptor (PR) in accordance to Remmele and Stegner [10] . It was defined by the product of a proportion (0, none; 1, <10%; 2, 10-50%; 3, 51-80%; 4, 81-100%) and an intensity score (0, no staining; 1, weak; 2, moderate; 3, strong) [10] . The median was used to dichotomize the samples into FAK positive (high expression) and negative (low expression) tumors.
Statistical Analyses
Statistical analysis was performed with the SPSS statistical software program, version 22.0 (SPSS Inc., Chicago, IL, USA). Multivariate analyses were conducted using Cox regression analysis to evaluate the association between FAK expression (FAK positive vs. negative) in the BC samples and established prognostic factors such as age at diagnosis (<50 years vs. 50 years), tumor size (pT1 vs. pT2), histological grade (grade 1 and 2 vs. grade 3), hormone receptor status (ER or PR immunoreactive score (IRS) 1 or higher vs. IRS 0) and HER2 status (HER2 3+ or HER2 2+ and Fish positive vs. HER2 0, 1+ and HER2 2+ and Fish negative). Ki-67 was divided in low ( 20% positive cells) and high (>20%). Death from BC or unrelated to BC, and metastasis or local relapse were documented. Metastasis-free survival (MFS) was defined as the time between surgery and diagnosis of metastasis. Disease-free survival (DFS) was defined as the time between the date of surgery and the date of loco-regional or metastatic recurrence, BC related death or lost follow-up. Overall survival (OS) was defined as time between the date of surgery and the date of death through any cause. The correlation between FAK and clinico-pathological parameters was assessed using chi-square statistics. Univariate and multivariate Cox regression analyses were performed. Survival rates were calculated by the Kaplan-Meier method and 
Subgroup Analyses
In a next step, we examined the prognostic impact of FAK within different molecular subtypes. Considering the different molecular subtypes, the prognostic effect for DSF was most pronounced in ER + HER2 -carcinomas (HR 1.76, 95% CI 1.05-2.97, p = 0.033). Kaplan-Meier plots showed an 80.2% 5-year DFS rate for FAK-positive and an 88.2% 5-year DFS rate for FAK-negative patients (p = 0.031) (fig. 3) . The association of FAK with DFS was most pronounced in luminal B-like BC (HR 2.32, 95% CI 1.20-4.48, p = 0.012). FAK expression failed to show a significant association with all other endpoints in any other subtypes of BC (table 3) .
Discussion
Prognostic factors play a crucial role in the adequate treatment of patients with early BC. In our retrospective study, expression of FAK was associated with poor DFS in node-negative BC. The prognostic significance of FAK was shown for DFS in univariate analysis, especially in ER + BC. This effect was most pronounced in luminal B-like tumors. However, caution in interpreting our finding is necessary due to the very small sample size of this subgroup (n = 21). In multivariate analyses, FAK failed to show any association with survival. We did not differentiate between phosphorylated/activated and inactivated FAK proteins. Madan et al. [11] performed this differentiation, but the hypothesis that activated FAK (FAK pY 397 , main autophosphorylation site) was associated with tumor invasiveness was not verified. In addition to the biological aspects, there is a methodical challenge in evaluating the influence of FAK in prognosis for BC as there is no standardized cut-off value. In our study, based on results of preliminary data, we chose the median as the cut-off value [12] [13] [14] , resulting in groups of similar size. Next, we evaluated the influence of FAK in different molecular subtypes. Our results highlight the most pronounced prognostic relevance of FAK for DFS in ER + HER2 -BC and especially in luminal B-like tumors. In particular, for ER + HER2
-BC, studies on prognostic factors are of utmost importance for a more precise differentiation between high-and low-risk patients with additional therapeutic options. There has been no clear consensus in publications about the relevance of FAK in various molecular subtypes. Alexopoulou et al. [14] showed a correlation between FAK expression and luminal A as well as triple-negative tumor cells. Conversely, Lark and co-workers [15] discussed a possible molecular interaction between FAK and HER2 in which HER2 regulates FAK phosphorylation. This hypothesis was followed by the findings of Schmitz et al. [16] , who found no prognostic influence, concluding that this may have been due to the composition of their cohort. Like our study population, their cohort comprised patients with early tumor stages. Golubovskaya et al. [17] described contrasting correlations. However, most of the authors regarded the limited number of patients and the heterogeneity of the study cohorts as possible causes for the inconsistent results. The challenge of comparability also results from variations in the FAK detection (phosphorylation status, cell compartment, etc.).
Recently, first results of an ATP-competitive FAK inhibitor (PF-562271) were published and showed promising initial results [18] . Several FAK inhibitors are currently in clinical testing (PF-562271, PF-04554878, GSK2256098, VS-4718, VS-6062, VS-6063, and BI853520) [19, 20] . Based on our results, it is possible that the implementation of FAK inhibitors may be most effective in the cohort of luminal B BC, perhaps in combination with an endocrine therapy, as known for other combinations such as everolimus or palbociclib. In particular, in the context of overcoming endocrine resistance, the use of an FAK inhibitor would be a further therapeutic option. Further pre-clinical and clinical studies are needed to answer these questions.
All previous studies on the prognostic impact of FAK have included cohorts of patients treated with adjuvant therapies, which may have confounded the prognostic impact of this biomarker. A particular strength of our study is the selection of our cohort of patients. None of the patients with node-negative BC had received adjuvant systemic therapy, thus excluding this potential bias. A potential weakness of our study is that no differentiation of the activity state of FAK was performed. Such a differentiation analysis may provide further information on the prognostic role of FAK in various subtypes of BC. Another potential weakness of our study is the limited number of patients (n = 335), especially in the subgroup analyses.
In conclusion, our study showed that FAK protein expression was associated with DFS in univariate but not in multivariate analyses. Prognostic relevance was most pronounced in ER + HER2
-BC and especially in luminal B-like tumors. This might lead to a preferential investigation of FAK inhibitors in these patients.
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